CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 444 filers reported holding CRISPR THERAPEUTICS AG in Q1 2022. The put-call ratio across all filers is 0.99 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $568,000 | -67.3% | 7,500 | -51.6% | 0.06% | -67.4% |
| Q3 2021 | $1,736,000 | +12.2% | 15,506 | +62.2% | 0.19% | +12.7% |
| Q2 2021 | $1,547,000 | -6.6% | 9,558 | -29.7% | 0.17% | -11.7% |
| Q1 2021 | $1,656,000 | -20.7% | 13,590 | -0.3% | 0.19% | -22.3% |
| Q4 2020 | $2,087,000 | +143.5% | 13,629 | +32.9% | 0.24% | +105.1% |
| Q3 2020 | $857,000 | +9.7% | 10,252 | -3.5% | 0.12% | +1.7% |
| Q2 2020 | $781,000 | +59.1% | 10,625 | -4.0% | 0.12% | +81.2% |
| Q3 2018 | $491,000 | -54.3% | 11,070 | -39.5% | 0.06% | -64.6% |
| Q2 2018 | $1,074,000 | – | 18,285 | – | 0.18% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |